Endologix Announces First U.S. Implant of AFXâ„¢ Endovascular AAA System

IRVINE, Calif., Aug. 8, 2011 /PRNewswire/ — Endologix, Inc.
(Nasdaq:
ELGX), developer and marketer of minimally invasive treatments
for aortic disorders, announced today that the first U.S.
commercial implant of the Company’s AFX™ Endovascular AAA
System was performed at Edward Hines, Jr. VA Hospital in Chicago,
IL. The procedure was performed by Ross Milner, M.D., F.A.C.S.,
Associate Professor and Chief of Vascular Surgery &
Endovascular Therapy at Loyola University in Chicago, IL.

Dr. Milner commented, “We are excited to be the first hospital
in the U.S. to bring the benefits of the new AFX system to a
patient in our local community. The device builds on the compelling
clinical evidence supporting Endologix’s unique anatomical fixation
technology with an enhanced, lower profile delivery system and new
graft material. The 17Fr introducer sheath and integrated delivery
system make it easy to use in a wide range of patient anatomies.
The AFX system performed very well during the procedure; the
delivery and deployment of the stent graft was quick and precise,
and post-procedure imaging confirmed that the aneurysm was
effectively sealed.”

John McDermott, President and Chief Executive Officer of
Endologix, commented, “We are pleased with the results from the
initial implant and would like to thank Dr. Milner and his team for
performing the procedure. We look forward to providing this
exciting new endovascular device to physicians and patients in the
U.S. in September.”

About Endologix, Inc.Endologix, Inc. develops and
manufactures minimally invasive treatments for aortic disorders.
The Company’s focus is endovascular stent grafts for the treatment
of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall
of the aorta, the largest artery in the body, resulting in a
balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if le

‘/>”/>

SOURCE